JP2024504378A5 - - Google Patents

Info

Publication number
JP2024504378A5
JP2024504378A5 JP2023544345A JP2023544345A JP2024504378A5 JP 2024504378 A5 JP2024504378 A5 JP 2024504378A5 JP 2023544345 A JP2023544345 A JP 2023544345A JP 2023544345 A JP2023544345 A JP 2023544345A JP 2024504378 A5 JP2024504378 A5 JP 2024504378A5
Authority
JP
Japan
Prior art keywords
compound according
group
optionally substituted
formula
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023544345A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024504378A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/070321 external-priority patent/WO2022159981A1/en
Publication of JP2024504378A publication Critical patent/JP2024504378A/ja
Publication of JP2024504378A5 publication Critical patent/JP2024504378A5/ja
Pending legal-status Critical Current

Links

JP2023544345A 2021-01-25 2022-01-24 トリアジン化合物ならびにこれを作製する方法および使用する方法 Pending JP2024504378A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163141316P 2021-01-25 2021-01-25
US63/141,316 2021-01-25
PCT/US2022/070321 WO2022159981A1 (en) 2021-01-25 2022-01-24 Triazine compounds and methods of making and using the same

Publications (2)

Publication Number Publication Date
JP2024504378A JP2024504378A (ja) 2024-01-31
JP2024504378A5 true JP2024504378A5 (cg-RX-API-DMAC7.html) 2025-01-30

Family

ID=82549984

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023544345A Pending JP2024504378A (ja) 2021-01-25 2022-01-24 トリアジン化合物ならびにこれを作製する方法および使用する方法

Country Status (4)

Country Link
US (1) US20250188062A1 (cg-RX-API-DMAC7.html)
EP (1) EP4281447A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024504378A (cg-RX-API-DMAC7.html)
WO (1) WO2022159981A1 (cg-RX-API-DMAC7.html)

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1620528A1 (de) * 1965-12-31 1970-06-11 Thomae Gmbh Dr K Verfahren zur Herstellung von neuen basisch substituierten s-Triazinen
US5099019A (en) * 1985-09-12 1992-03-24 Upjohn Company Amines useful in producing pharmaceutically active CNS compounds
JPS6455557A (en) * 1987-08-26 1989-03-02 Fuji Photo Film Co Ltd Silver halide color photographic sensitive material
IT1240630B (it) * 1990-04-11 1993-12-17 Ministero Del Uni E Della Rice Sali di composti triazinici con acidi ossigenati del fosforo
JPH11158073A (ja) * 1997-09-26 1999-06-15 Takeda Chem Ind Ltd アデノシンa3拮抗剤
WO2008154798A1 (fr) * 2007-06-15 2008-12-24 Peking University Composés photosensibles de la n,n-dialkylamidophényl-dipyrazolyl triazine, leurs complexes d'europium et leurs procédés de préparation
US8415340B2 (en) * 2007-07-25 2013-04-09 Bristol-Myers Squibb Company Triazine kinase inhibitors
WO2009035671A1 (en) * 2007-09-12 2009-03-19 Janssen Pharmaceutica N.V. Substituted nitrogen-containing heteroaryl derivatives useful as modulators of the histamine h4 receptor
MY155653A (en) * 2008-05-23 2015-11-13 Wyeth Llc Triazine compounds as p13 kinase and mtor inhibitors
GB2465405A (en) * 2008-11-10 2010-05-19 Univ Basel Triazine, pyrimidine and pyridine analogues and their use in therapy
CN101838476B (zh) * 2009-03-18 2013-03-20 北京大学 一类有机荧光染料化合物及其合成方法与应用
CA2767008C (en) * 2009-07-07 2018-01-30 Pathway Therapeutics, Inc. Pyrimidinyl and 1,3,5-triazinyl benzimidazoles and their use in cancer therapy
ES2570177T3 (es) * 2010-08-10 2016-05-17 Astellas Pharma Inc Compuesto heterocíclico
GB201112607D0 (en) * 2011-07-22 2011-09-07 Glaxo Group Ltd Novel compounds
US9481670B2 (en) * 2011-01-25 2016-11-01 Sphaera Pharma Pte. Ltd. Triazine compounds
CN106608869B (zh) * 2015-10-27 2020-08-04 中国科学院上海药物研究所 一类组蛋白去甲基化酶jmjd3抑制剂及其制备方法和用途
CN108727369B (zh) * 2017-04-25 2023-06-09 广东东阳光药业有限公司 流感病毒复制抑制剂及其用途
WO2020141439A1 (en) * 2018-12-31 2020-07-09 Integral Biosciences Private Limited Heterocyclic compounds as mutant idh inhibitors
CN114007671B (zh) * 2019-04-26 2024-06-14 休斯敦大学体系 用于治疗上皮组织的慢性炎性损伤、化生、发育异常和癌症的方法和组合物

Similar Documents

Publication Publication Date Title
JP2024504932A5 (cg-RX-API-DMAC7.html)
JP2024518554A5 (cg-RX-API-DMAC7.html)
JP2023500532A5 (cg-RX-API-DMAC7.html)
JP2017518959A5 (cg-RX-API-DMAC7.html)
SI20818B (sl) N-heterocikliäśni derivati kot nos inhibitorji
JP2012236838A5 (cg-RX-API-DMAC7.html)
RU2009113019A (ru) Способы получения 1,2,4-оксадиазолбензойных кислот
JP2012021003A5 (cg-RX-API-DMAC7.html)
JP2004525117A5 (cg-RX-API-DMAC7.html)
JP2021530442A5 (cg-RX-API-DMAC7.html)
CN114014842B (zh) 一种杂环酮类化合物与其组合物及其制备方法和应用
RU2013138226A (ru) Способы и соединения, пригодные для получения конденсированных аминодигидротиазиновых производных
RU2011103997A (ru) Способ получения производных r-бета-аминофенилмасляной кислоты
JP2024516033A5 (cg-RX-API-DMAC7.html)
ES2202375T3 (es) Cristalizacion de levobupivacaina y sus analogos.
JP2003503384A (ja) 置換シクロペンタン誘導体の調製方法及びその新規結晶構造
JPWO2021187531A5 (cg-RX-API-DMAC7.html)
RU2011149550A (ru) Соединения о-имино-изомочевины и их полимеризуемые композиции
JP2023511152A5 (cg-RX-API-DMAC7.html)
CZ2017772A3 (cs) Způsob přípravy N-[4-(2-{[2-(4-methansulfonamidofenoxy)ethyl](methyl)amino}ethyl)fenyl]methansulfonamidu (Dofetilidu)
RU2507194C2 (ru) Способ получения оптически активных альфа-аминоацеталей
EP3854794B1 (en) Tlr8 agonist
JP2011511053A (ja) ボリノスタットの新規な製造方法
US20100087653A1 (en) Novel process for the preparation of lercanidipine
CN1053655C (zh) 制备旋光纯的氨基醇的方法